Related references
Note: Only part of the references are listed.Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies
Paolo Tarantino et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2022)
Benefits and challenges of antibody drug conjugates as novel form of chemotherapy
Syeda Warisul Fatima et al.
JOURNAL OF CONTROLLED RELEASE (2022)
From AVATAR Mice to Patients: RC48-ADC Exerted Promising Efficacy in Advanced Gastric Cancer With HER2 Expression
Zuhua Chen et al.
FRONTIERS IN PHARMACOLOGY (2022)
Antibody-drug conjugates: Resurgent anticancer agents with multi-targeted therapeutic potential
Claudia Ceci et al.
PHARMACOLOGY & THERAPEUTICS (2022)
Antibody-drug conjugates to treat gastric cancer
Shigehiro Koganemaru et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2021)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Current treatment and recent progress in gastric cancer
Smita S. Joshi et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective
Masahiko Aoki et al.
GASTRIC CANCER (2021)
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
Yelena Y. Janjigian et al.
NATURE (2021)
Unlocking the potential of antibody-drug conjugates for cancer therapy
Joshua Z. Drago et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors
Yingying Xu et al.
GASTRIC CANCER (2021)
Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand?
Giandomenico Roviello et al.
GASTRIC CANCER (2021)
Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study
Zhi Peng et al.
CANCER COMMUNICATIONS (2021)
Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas
Antonio Pellino et al.
JOURNAL OF PERSONALIZED MEDICINE (2021)
Targeting the autophagy promoted antitumor effect of T-DM1 on HER2-positive gastric cancer
Jinghui Zhang et al.
CELL DEATH & DISEASE (2021)
EV20/NMS-P945, a Novel Thienoindole Based Antibody-Drug Conjugate Targeting HER-3 for Solid Tumors
Emily Capone et al.
PHARMACEUTICS (2021)
Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
A. Bardia et al.
ANNALS OF ONCOLOGY (2021)
Efficacy of trastuzumab emtansine in Japanese patients with previously treated HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: A subgroup analysis of the GATSBY study
Kohei Shitara et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2020)
Antibody-Drug Conjugates: A Comprehensive Review
Puregmaa Khongorzul et al.
MOLECULAR CANCER RESEARCH (2020)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Mutational landscape of receptor guanylyl cyclase C: Functional analysis and disease-related mutations
Avipsa Bose et al.
IUBMB LIFE (2020)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
Kohei Shitara et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Patient Selection Strategies to Maximize Therapeutic Index of Antibody-Drug Conjugates: Prior Approaches and Future Directions
Marna Williams et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Intratumoral and intertumoral heterogeneity of HER2 immunohistochemical expression in gastric cancer
He Zhang et al.
PATHOLOGY RESEARCH AND PRACTICE (2020)
Evaluation and reflection on claudin 18.2 targeting therapy in advanced gastric cancer
Jianwei Zhang et al.
CHINESE JOURNAL OF CANCER RESEARCH (2020)
HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
Gabriel Rinnerthaler et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Antibody-Drug Conjugate-Based Therapeutics: State of the Science
Michael J. Birrer et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Targeting Trop-2 in solid tumors: future prospects
Saif Zaman et al.
ONCOTARGETS AND THERAPY (2019)
Acquired Resistance to Antibody-Drug Conjugates
Denis M. Collins et al.
CANCERS (2019)
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study
Kohei Shitara et al.
LANCET ONCOLOGY (2019)
Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes
Meghdad Abdollahpour-Alitappeh et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985)
Zhuyu Xu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma
Christoph Rohde et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2019)
IgG Fc engineering to modulate antibody effector functions
Xinhua Wang et al.
PROTEIN & CELL (2018)
Resistance to Antibody-Drug Conjugates
Sara Garcia-Alonso et al.
CANCER RESEARCH (2018)
A monomethyl auristatin E-conjugated antibody to guanylyl cyclase C is cytotoxic to target-expressing cells in vitro and in vivo
Melissa Gallery et al.
PLOS ONE (2018)
TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study
Yung-Jue Bang et al.
CANCER RESEARCH AND TREATMENT (2018)
DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance
Naoki Takegawa et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
Aditya Bardia et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
Peter C. Thuss-Patience et al.
LANCET ONCOLOGY (2017)
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial
Veronique Dieras et al.
LANCET ONCOLOGY (2017)
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial
Ian E. Krop et al.
LANCET ONCOLOGY (2017)
Strategies and challenges for the next generation of antibody drug conjugates
Alain Beck et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Antibody-drug conjugate directed against the guanylyl cyclase antigen for the treatment of gastrointestinal malignancies
Khaldoun Almhanna et al.
PHARMACOLOGY & THERAPEUTICS (2017)
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-Drug Conjugate for the Treatment of Diverse Epithelial Cancers: Safety and Pharmacokinetics
Allyson J. Ocean et al.
CANCER (2017)
Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity
Carla Rios-Luci et al.
CANCER RESEARCH (2017)
Phase I Study of the Investigational Anti-Guanylyl Cyclase Antibody-Drug Conjugate TAK-264 (MLN0264) in Adult Patients with Advanced Gastrointestinal Malignancies
Khaldoun Almhanna et al.
CLINICAL CANCER RESEARCH (2016)
Antibody-drug conjugates for cancer therapy
Anish Thomas et al.
LANCET ONCOLOGY (2016)
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers
Thomas M. Cardillo et al.
BIOCONJUGATE CHEMISTRY (2015)
SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm
Kevin J. Hamblett et al.
CANCER RESEARCH (2015)
Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan)
Robert M. Sharkey et al.
CLINICAL CANCER RESEARCH (2015)
Tumor Cells Chronically Treated with a Trastuzumab-Maytansinoid Antibody-Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments
Frank Loganzo et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Building better monoclonal antibody-based therapeutics
George J. Weiner
NATURE REVIEWS CANCER (2015)
Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model
Yoriko Yamashita-Kashima et al.
ONCOLOGY REPORTS (2013)
Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance
Yelena V. Kovtun et al.
CANCER RESEARCH (2010)
High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg®) treatment in acute myeloid leukemia patients
VHJ van der Velden et al.
LEUKEMIA (2004)